BIOPHARMA
ByIs AION Labs Redefining AI Drug Discovery by Incubating Pharma-Native Startups from the Inside Out?
Strategic Overview AION Labs represents a structurally different model in the AI–biopharma landscape: a venture studio co-created by…
Is Ignota Labs Turning Pharma’s Failed Assets into a New AI-Driven Value Class?
Strategic Overview Ignota Labs is taking a fundamentally different approach to AI in biopharma—one that focuses not on…
Is XtalPi Emerging as Pharma’s AI Engine for Molecular Property Prediction and Manufacturability at Scale?
Strategic Overview XtalPi is carving out a differentiated position in the AI-biopharma landscape by focusing on one of…
Is Owkin Building the Clinical Data Intelligence Layer as Pharma Commits Over $1.5 Billion to Federated AI Partnerships?
Strategic Overview Owkin is positioning itself at the center of a critical bottleneck in drug development: access to…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
